Relevant bibliographies by topics / Actinium / Journal articles
To see the other types of publications on this topic, follow the link: Actinium.

Journal articles on the topic 'Actinium'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 August 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Actinium.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

WALL, GREG. "ACTINIUM." Chemical & Engineering News 81, no. 36 (September 8, 2003): 162. http://dx.doi.org/10.1021/cen-v081n036.p162.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Deblonde, Gauthier J. P., and Rebecca J. Abergel. "Active actinium." Nature Chemistry 8, no. 11 (October 21, 2016): 1084. http://dx.doi.org/10.1038/nchem.2653.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gyurkocza, Boglarka, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R. Litzow, Nebu V. Koshy, Patrick Stiff, et al. "Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies." Blood 138, Supplement 1 (November 5, 2021): 1791. http://dx.doi.org/10.1182/blood-2021-148497.

Full text
Abstract:
Abstract Background: Several targeted therapies have been recently approved as treatment options for acute myeloid leukemia (AML), however, complete remissions (CR) in relapsed/refractory (R/R) patients remain low. Due to suboptimal responses to standard therapies, most of these patients do not receive an allogeneic hematopoietic cell transplant (HCT). In addition, AML patients ≥55 years have poor tolerance and high morbidity from a myeloablative HCT. The SIERRA trial (Study of Iomab-B in Elderly Relapsed or Refractory AML) has been investigating the use of Iomab-B, an 131I-labeled anti-CD45 monoclonal antibody, to reduce relapse in patients with active, R/R AML who receive HCT as compared to Conventional Care (CC) therapies. With the recent approval of various targeted therapies like BCL-2 inhibitors (e.g., venetoclax), FLT-3 inhibitors (e.g., midostaurin and gilteritinib) and IDH inhibitors (e.g., ivosidenib), the protocol was amended to include patients refractory to these therapies. We are reporting on the success rate of engraftment and tolerability of Iomab-B among the CC patients who cross-over to receive Iomab-B and HCT after failing these agents. Methods: Approximately 150 older patients with R/R AML are to be randomized (1:1) to receive Iomab-B followed by fludarabine, total body irradiation (2 Gy) and allogeneic HCT, or to conventional care (CC). CC patients receive physician's choice of therapy, including targeted therapies, and may proceed to standard of care allogeneic HCT if they achieve CR. CC patients not achieving CR may cross over to Iomab-B-based HCT. Results: Available data for 136 patients (>90% of target enrollment; median age 65) demonstrated they had a median of 3 (range: 1-7) prior lines of AML therapies. Median marrow blast at time of study entry was 25%. Prior to enrollment, 85 (63%) patients received targeted therapies, including BCL-2 inhibitors (62%), FLT-3 inhibitors (18%), IDH inhibitors (7%) and others (13%; e.g., gemtuzumab ozogamicin). Among the 50 evaluable patients in the Iomab-B group that received HCT, all successfully engrafted after a median radiation dose delivered to marrow of 14.7 Gy (range: 4.6 - 44.6) with a median time to neutrophil and platelet engraftment of 14.5 (range: 9-28) and 18 (range: 4-58) days, respectively. Of 63 patients randomized to the CC arm and with data available, 11 (17%) achieved CR and proceeded to standard of care HCT without Iomab-B while 52 (83%) did not respond to CC therapy. Twenty-seven of 63 (43%) CC patients received targeted therapy, of whom 21 received venetoclax with hypomethylating agents (HMA) or low-dose Cytarabine (LDAC). Seven of the 27 (26%) CC patients remission after targeted therapy and received standard of care HCT. Of the 20 patients who did not respond to targeted therapies, 11 (55%) crossed-over and received Iomab-B/HCT with a median radiation dose delivered to marrow of 18 Gy (range: 12.6 - 22.6). Median time to neutrophil and platelet engraftment was 12 (range: 10-27) and 20 (range: 15-38) days, respectively. Safety data are available for 103 transplanted patients in both groups and are presented in table. The incidence of Grade ≥3 febrile neutropenia (FN) was 37% vs 55%, sepsis 5% vs 30%, and mucositis 10% vs 20% in the Iomab-B group compared to all transplanted patients in the CC group. In patients who received targeted therapy and HCT (crossover or standard HCT), incidences of FN, sepsis and mucositis were 39%, 28% and 22%, respectively. Conclusion: SIERRA trial patients not achieving CR with recently approved targeted therapies who then crossed-over to receive HCT with Iomab-B successfully engrafted. Time to engraftment was similar to those who were randomized to receive Iomab-B and HCT. Available data suggest incidences of sepsis and mucositis are lower in the Iomab-B group. (www.sierratrial.com or clinicaltrials.gov NCT02665065) Figure 1 Figure 1. Disclosures Gyurkocza: Actinium Pharmaceutical Inc.: Research Funding. Nath: Actinium: Consultancy, Honoraria; Incyte: Consultancy, Honoraria. Litzow: Amgen: Research Funding; Biosight: Other: Data monitoring committee; Jazz: Other: Advisory Board; Pluristem: Research Funding; Astellas: Research Funding; Actinium: Research Funding; Omeros: Other: Advisory Board; AbbVie: Research Funding. Koshy: Astellas; Actinium Pharmaceuticals: Other: Principal Investigator, SIERRA Trial, Actinium, Speakers Bureau. Stiff: Seagen: Research Funding; Incyte: Research Funding; Gamida Cell: Research Funding; Janssen: Research Funding; CRISPR Therapeutics: Consultancy, Honoraria; Kite, a Gilead Company: Research Funding; Macrogenics: Research Funding; Bristol Myers Squibb: Research Funding; Cellectar: Research Funding; BioLineRX: Research Funding; MorphoSys: Consultancy, Honoraria; Amgen: Research Funding; Karyopharm: Consultancy, Honoraria; Cellectar: Research Funding; Actinium: Research Funding. Abhyankar: Incyte/Therakos: Consultancy, Research Funding, Speakers Bureau. Hari: Karyopharm: Consultancy; Millenium: Membership on an entity's Board of Directors or advisory committees, Research Funding; Adaptive Biotech: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Celgene-BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau. Chen: Actinium Pharmaceuticals: Other: Principal Investigator, SIERRA Trial, Actinium. Sabloff: Novartis: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; TaiHo: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Astellas: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Jaxx: Membership on an entity's Board of Directors or advisory committees; ROCHE: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees. Orozco: Actinium Pharmaceuticals: Other: Principal Investigator, SIERRA Trial, Actinium, Research Funding. Foran: abbvie: Research Funding; revolution medicine: Honoraria; novartis: Honoraria; certara: Honoraria; actinium: Research Funding; OncLive: Honoraria; aptose: Research Funding; trillium: Research Funding; gamida: Honoraria; takeda: Research Funding; boehringer ingelheim: Research Funding; bms: Honoraria; taiho: Honoraria; syros: Honoraria; sanofi aventis: Honoraria; pfizer: Honoraria; servier: Honoraria; kura: Research Funding; h3bioscience: Research Funding; aprea: Research Funding; sellas: Research Funding; stemline: Research Funding. Jamieson: Actinium Pharmaceuticals: Other: Principal Investigator, SIERRA Trial, Actinium. Magalhaes-Silverman: Actinium Pharmaceuticals; Incyte; Marker Therapeutics: Other: Principal Investigator, SIERRA Trial, Actinium, Research Funding. Schuster: Takeda: Consultancy, Speakers Bureau; MorphoSys Ag: Consultancy, Speakers Bureau; Astellas: Consultancy, Speakers Bureau; Intellisphere: Consultancy, Speakers Bureau; AbbVie Incorporated: Consultancy, Speakers Bureau; Pharmacyclics: Consultancy, Research Funding, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Epizyme: Consultancy, Speakers Bureau; Bristol Myers Squibb: Consultancy, Speakers Bureau; BeiGene: Consultancy, Speakers Bureau; Actinium Pharmaceuticals: Other: Principal Investigator, SIERRA Trial, Actinium Pharmaceuticals, Research Funding; Rafael Pharmaceuticals: Research Funding; GSK: Research Funding; AlloVir: Research Funding; Incyte: Research Funding; Seattle Genetics: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Genentech: Consultancy, Speakers Bureau; Amgen: Consultancy, Current equity holder in publicly-traded company, Speakers Bureau; Celgene: Consultancy, Current equity holder in publicly-traded company, Speakers Bureau. Law: Actinium Pharmaceuticals: Research Funding; Novartis: Consultancy. Levy: Takeda, Celgene, Seattle Genetics, AbbVie, Jazz Pharmaceuticals, Gilead Sciences, Bristol-Myers Squibb, Amgen, Spectrum Pharmaceuticals,Janssen.: Consultancy. Lazarus: Bristol Myer Squibb: Membership on an entity's Board of Directors or advisory committees. Giralt: PFIZER: Membership on an entity's Board of Directors or advisory committees; AMGEN: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; SANOFI: Membership on an entity's Board of Directors or advisory committees; CELGENE: Membership on an entity's Board of Directors or advisory committees; JAZZ: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; JENSENN: Membership on an entity's Board of Directors or advisory committees; Actinnum: Membership on an entity's Board of Directors or advisory committees. Berger: Actinium Pharmaceuticals, Inc: Current Employment. Spross: Actinium Pharmaceuticals: Current Employment, Current holder of stock options in a privately-held company. Desai: Actinium Pharmaceuticals: Current Employment, Current holder of stock options in a privately-held company. Reddy: Actinium Pharmaceuticals: Current Employment, Current holder of stock options in a privately-held company. Pagel: AstraZeneca: Consultancy; MEI Pharma: Consultancy; Epizyme: Consultancy; Actinium Pharmaceuticals: Consultancy; Kite, a Gilead Company: Consultancy; BeiGene: Consultancy; Pharmacyclics/AbbVie: Consultancy; Gilead: Consultancy; Incyte/MorphoSys: Consultancy.
APA, Harvard, Vancouver, ISO, and other styles
4

Eliav, Ephraim, Sergei Shmulyian, Uzi Kaldor, and Yasuyuki Ishikawa. "Transition energies of lanthanum, actinium, and eka-actinium (element 121)." Journal of Chemical Physics 109, no. 10 (September 8, 1998): 3954–58. http://dx.doi.org/10.1063/1.476995.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Yushchenko, V., V. Gopka, A. V. Yushchenko, A. Shavrina, Ya Pavlenkо, and S. Vasil’eva. "ACTINIUM ABUNDANCES IN STELLAR ATMOSPHERES." Odessa Astronomical Publications 34 (December 3, 2021): 70–73. http://dx.doi.org/10.18524/1810-4215.2021.34.244288.

Full text
Abstract:
This paper presents a study of radioactive actinium in the atmospheres of stars located in galaxies with different chemical evolution history – namely, Przybylski's Star (HD 101065) in the Milky Way and the red supergiant PMMR27 in the Small Magellanic Cloud; it also reports the findings of the previous research of the red supergiant RM 1-667 in the Large Magellanic Cloud and the red giant BL138 in the Fornax dwarf spheroidal galaxy. The actinium abundance is close to that of uranium in the atmospheres of certain stars in the Milky Way’s halo and in the atmosphere of Arcturus. The following actinium abundances have been obtained (in a scale of lg N(H) = 12): for the red supergiants PMMR27 and RM 1- 667 lg N(Ac) = -1.7 and lg N(Ac) = -1.3, respectively, and for the red giant BL138 lg N(Ac) = -1.6. The actinium abundance in the atmosphere of Przybylski's Star (HD 101065) is lg N(Ac) = `0.94±0.09, which is more than two orders of magnitude higher than those in the atmospheres of the other studied stars.
APA, Harvard, Vancouver, ISO, and other styles
6

Durrani, Matin. "From actinium to zinc." Physics World 32, no. 8 (August 2019): 50. http://dx.doi.org/10.1088/2058-7058/32/8/39.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Zielińska, B., and A. Bilewicz. "The hydrolysis of actinium." Journal of Radioanalytical and Nuclear Chemistry 261, no. 1 (2004): 195–98. http://dx.doi.org/10.1023/b:jrnc.0000030956.61947.c5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tsoupko-Sitnikov, V., Yu Norseev, and V. Khalkin. "Generator of actinium-225." Journal of Radioanalytical and Nuclear Chemistry Articles 205, no. 1 (April 1996): 75–83. http://dx.doi.org/10.1007/bf02040552.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pratiwi, Anita Puji, Trapsilo Prihandono, and Sri Handono Budi Prastowo. "Numerical Solution of Radioactive Core Decay Activity Rate of Actinium Series Using Matrix Algebra Method." Jurnal Penelitian Pendidikan IPA 7, no. 3 (July 7, 2021): 395. http://dx.doi.org/10.29303/jppipa.v7i3.716.

Full text
Abstract:
The Actinium 235 series is one of the radioactive series which is widely used as a raw material for reactors and nuclear activities. The existence of this series is found in several countries such as West USA, Canada, Australia, South Africa, Russia, and Zaire. The purpose of this study was to determine the activity value and the number of radioactive nucleus decay atoms on the actinium 235 rendered in a very long decay time of 4.3 x 109 years. The decay count in this study uses an algebraic matrix method to simplify the chain decay solution, which generally uses the concept of differential equations. The solution using this method can be computationally simulated using the Matlab program. This study indicates that the value of the decay activity experienced by each element in this series is the same, which is equal to 2,636 x 1011 Bq. This condition causes the actinium 235 series to experience secular equilibrium because the half-life of the parent nuclide is greater than the nuclide derivatives. The decay activity of the radioactive nucleus under the actinium 235 series is strongly influenced by the half-life of the nuclides, the decay constants, and the number of atoms after decay
APA, Harvard, Vancouver, ISO, and other styles
10

Hoffman, Darleane C. "Glenn Theodore Seaborg. 19 April 1912 — 25 February 1999." Biographical Memoirs of Fellows of the Royal Society 53 (January 2007): 327–38. http://dx.doi.org/10.1098/rsbm.2007.0021.

Full text
Abstract:
Glenn T. Seaborg was a world-renowned nuclear chemist, educator, scientific adviser to ten US presidents, humanitarian, and Nobel laureate in chemistry. He is probably best known for his leadership of the team that in 1941 accomplished the first chemical separation and positive identification of plutonium and for his ‘revolutionary’ actinide concept in which he placed the first 14 elements heavier than actinium in the periodic table of elements as a 5f transition series under the lanthanide 4f transition series. He went on to be co-discoverer of nine elements beyond plutonium, culminating in 1974 in the production of element 106, later named seaborgium in his honour.
APA, Harvard, Vancouver, ISO, and other styles
11

Kozimor, Stosh, Enrique Batista, Kevin John, Eva Birnbaum, Veronika Mocko, Laura Lilley, Amanda Morgenstern, and Benjamin Stein. "Coordination Chemistry of +3 Actinium." Journal of Medical Imaging and Radiation Sciences 50, no. 4 (December 2019): S78—S79. http://dx.doi.org/10.1016/j.jmir.2019.11.041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Kozimor, Stosh, Enrique Batista, Kevin John, Eva Birnbaum, Veronika Mocko, Laura Lilley, Amanda Morgenstern, and Benjamin Stein. "Coordination Chemistry of +3 Actinium." Journal of Medical Imaging and Radiation Sciences 50, no. 1 (March 2019): S11. http://dx.doi.org/10.1016/j.jmir.2019.03.036.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Dzhuzha, D., and S. Myasoyedov. "Radionuclide therapy with alpha-emitters." Radiation Diagnostics, Radiation Therapy, no. 4 (2019): 37–47. http://dx.doi.org/10.37336/2707-0700-2019-4-4.

Full text
Abstract:
In this review the main streams of using alpha-emitters radium-223, actinium-225, bismuth-213, astatine-211 in complex treatment of malignant tumors are reviewed. The features of radiobiological actions of alpha-emission make its more effective in hundred times than beta-emission. The efficacy of this kind of radionuclide therapy does not dependent from chemoresistance and radioresistance to beta-emitters. The results of experimental and initial clinical investigation, which indicate on promising further investigations in this direction, were revealed. Key words: radionuclide therapy of malignant tumors, alpha-emitters, radium-223, actinium-225, bismuth-213, astatine-211.
APA, Harvard, Vancouver, ISO, and other styles
14

Kazakov, A. G., B. L. Garashchenko, R. Yu Yakovlev, S. E. Vinokurov, S. N. Kalmykov, and B. F. Myasoedov. "Generator of Actinium-228 and a Study of the Sorption of Actinium by Carbon Nanomaterials." Radiochemistry 62, no. 5 (May 2020): 592–98. http://dx.doi.org/10.1134/s1066362220050057.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Putri, Maharani Karunia, Albertus Djoko Lesmono, and Alex Harijanto. "SIMULASI ENERGI IKAT DAN ENERGI DISINTEGRASI PELURUHAN UNSUR RADIOAKTIF DERET AKTINIUM BERDASARKAN MODEL INTI TETESAN CAIRAN (TELAAH KLASIK)." JURNAL PEMBELAJARAN FISIKA 10, no. 1 (March 31, 2021): 22. http://dx.doi.org/10.19184/jpf.v10i1.23583.

Full text
Abstract:
The purpose of this research is to make simulation with Matlab application to calculate the binding energy and disintegration energy of Actinium series based of liquid drop model approach. This research is experimental description. The steps: 1) prepare literature studies of elements in the radioactive process; 2) reviewing some literatures; 3) do calculation simulation; 4) analyze and discuss the results of calculations; 5) conclude the research results. The calculation results show that the binding energy value of the Actinium Series based of liquid drop model approach is in accordance with the theory where the binding energy is directly proportional to the mass and the number of particles, so that the binding energy decreases in linear graph. The largest binding energy owned by 92U235 element is 1786,751 MeV. While the smallest binding energy owned by the 81Tl20 element is 1616,311 MeV. The disintegration energy found in the radioactive actinium series has a positive value, so this is in accordance with the conditions for the occurrence of decay, which is Q> 0. The largest disintegration energy produced from alpha decay by element 91Pa231 is 4.9335 MeV and the smallest binding energy generated from beta decay by the element 90Th231 is 0,0018 MeV. Key Word: Disintegration Energy, Binding Energy, Liquid Drop Model Approach.
APA, Harvard, Vancouver, ISO, and other styles
16

Rick Mullin. "SpectronRX plans actinium-225 in Indiana." C&EN Global Enterprise 100, no. 22 (June 20, 2022): 11. http://dx.doi.org/10.1021/cen-10022-buscon14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Aldrich, Kelly E., Mila Nhu Lam, Cecilia Eiroa-Lledo, Stosh A. Kozimor, Laura M. Lilley, Veronika Mocko, and Benjamin W. Stein. "Preparation of an Actinium-228 Generator." Inorganic Chemistry 59, no. 5 (February 16, 2020): 3200–3206. http://dx.doi.org/10.1021/acs.inorgchem.9b03563.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Guminski, C. "The Ac-Hg (actinium-mercury) system." Journal of Phase Equilibria 16, no. 4 (August 1995): 332. http://dx.doi.org/10.1007/bf02645291.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Venkatraman, M., J. P. Neumann, and D. E. Peterson. "The Ac-Cr (Actinium-Chromium) system." Bulletin of Alloy Phase Diagrams 6, no. 5 (October 1985): 413–14. http://dx.doi.org/10.1007/bf02869495.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Kosynkin, V. D., S. D. Moiseev, and V. S. Vdovichev. "Cleaning rare earth elements from actinium." Journal of Alloys and Compounds 225, no. 1-2 (July 1995): 320–23. http://dx.doi.org/10.1016/0925-8388(94)07132-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Rick Mullin. "Firms launch an actinium-225 venture." C&EN Global Enterprise 101, no. 36 (October 30, 2023): 14. http://dx.doi.org/10.1021/cen-10136-buscon14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Peterson, D. E. "The Ac−Pt (Actinium-Platinum) system." Bulletin of Alloy Phase Diagrams 10, no. 4 (August 1989): 471–72. http://dx.doi.org/10.1007/bf02882382.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Rahman, A. K. M. Rezaur, Mahathe Hasan Babu, Mustofa Khalid Ovi, Md Mahiuddin Zilani, Israt Sultana Eithu, and Amit Chakraborty. "Actinium-225 in Targeted Alpha Therapy." Journal of Medical Physics 49, no. 2 (April 2024): 137–47. http://dx.doi.org/10.4103/jmp.jmp_22_24.

Full text
Abstract:
The utilization of actinium-225 (225Ac) radionuclides in targeted alpha therapy for cancer was initially outlined in 1993. Over the past two decades, substantial research has been conducted, encompassing the establishment of 225Ac production methods, various preclinical investigations, and several clinical studies. Currently, there is a growing number of compounds labeled with 225Ac that are being developed and tested in clinical trials. In response to the increasing demand for this nuclide, production facilities are either being built or have already been established. This article offers a concise summary of the present state of clinical advancements in compounds labeled with 225Ac. It outlines various processes involved in the production and purification of 225Ac to cater to the growing demand for this radionuclide. The article examines the merits and drawbacks of different procedures, delves into preclinical trials, and discusses ongoing clinical trials.
APA, Harvard, Vancouver, ISO, and other styles
24

Toro-González, M., R. Copping, S. Mirzadeh, and J. V. Rojas. "Multifunctional GdVO4:Eu core–shell nanoparticles containing 225Ac for targeted alpha therapy and molecular imaging." Journal of Materials Chemistry B 6, no. 47 (2018): 7985–97. http://dx.doi.org/10.1039/c8tb02173b.

Full text
Abstract:
Development of actinium-225 doped Gd0.8Eu0.2VO4 core–shell nanoparticles as multifunctional platforms for multimodal molecular imaging and targeted radionuclide therapy.
APA, Harvard, Vancouver, ISO, and other styles
25

Diamond, W. T., and C. K. Ross. "Actinium-225 production with an electron accelerator." Journal of Applied Physics 129, no. 10 (March 14, 2021): 104901. http://dx.doi.org/10.1063/5.0043509.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Brown, M. Alex. "Separation of radium and actinium using zirconia." Applied Radiation and Isotopes 185 (July 2022): 110238. http://dx.doi.org/10.1016/j.apradiso.2022.110238.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Skliarova, Hanna, Stephan Heinitz, Jasper Mermans, Dominic Maertens, Alexey Stankovskiy, Dennis Elema, and Thomas Cardinaels. "Towards Actinium-225 production at SCK CEN." Nuclear Medicine and Biology 96-97 (May 2021): S80—S81. http://dx.doi.org/10.1016/s0969-8051(21)00398-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Ürer, Güldem, and Leyla Özdemir. "The level structure of singly-ionized actinium." Journal of the Korean Physical Society 61, no. 3 (August 2012): 353–58. http://dx.doi.org/10.3938/jkps.61.353.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Kotovskii, A. A., N. A. Nerozin, I. V. Prokof’ev, V. V. Shapovalov, Yu A. Yakovshchits, A. S. Bolonkin, and A. V. Dunin. "Isolation of actinium-225 for medical purposes." Radiochemistry 57, no. 3 (May 2015): 285–91. http://dx.doi.org/10.1134/s1066362215030091.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Harris, Jack. "Actinium to zirconium and all in between." Physics World 15, no. 2 (February 2002): 46. http://dx.doi.org/10.1088/2058-7058/15/2/43.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Du, Yong, Angel Cortez, Anders Josefsson, Mohammadreza Zarisfi, Rebecca Krimins, Eleni Liapi, and Jessie R. Nedrow. "Preliminary evaluation of alpha-emitting radioembolization in animal models of hepatocellular carcinoma." PLOS ONE 17, no. 1 (January 21, 2022): e0261982. http://dx.doi.org/10.1371/journal.pone.0261982.

Full text
Abstract:
Hepatocellular carcinoma is the most common primary liver cancer and the fifth most frequently diagnosed cancer worldwide. Most patients with advanced disease are offered non-surgical palliative treatment options. This work explores the first alpha-particle emitting radioembolization for the treatment and monitoring of hepatic tumors. Furthermore, this works demonstrates the first in vivo simultaneous multiple-radionuclide SPECT-images of the complex decay chain of an [225Ac]Ac-labeled agent using a clinical SPECT system to monitor the temporal distribution. A DOTA chelator was modified with a lipophilic moiety and radiolabeled with the α-particle emitter Actinium-225. The resulting agent, [225Ac]Ac-DOTA-TDA, was emulsified in ethiodized oil and evaluated in vivo in mouse model and the VX2 rabbit technical model of liver cancer. SPECT imaging was performed to monitor distribution of the TAT agent and the free daughters. The [225Ac]Ac-DOTA-TDA emulsion was shown to retain within the HEP2G tumors and VX2 tumor, with minimal uptake within normal tissue. In the mouse model, significant improvements in overall survival were observed. SPECT-imaging was able to distinguish between the Actinium-225 agent (Francium-221) and the loss of the longer lived daughter, Bismuth-213. An α-particle emitting TARE agent is capable of targeting liver tumors with minimal accumulation in normal tissue, providing a potential therapeutic agent for the treatment of hepatocellular carcinoma as well as a variety of hepatic tumors. In addition, SPECT-imaging presented here supports the further development of imaging methodology and protocols that can be incorporated into the clinic to monitor Actinium-225-labeled agents.
APA, Harvard, Vancouver, ISO, and other styles
32

A. Scheinberg, David, and Michael R. McDevitt. "Actinium-225 in Targeted Alpha-Particle Therapeutic Applications." Current Radiopharmaceuticalse 4, no. 4 (October 1, 2011): 306–20. http://dx.doi.org/10.2174/1874471011104040306.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Ferrier, Maryline G., Benjamin W. Stein, Enrique R. Batista, John M. Berg, Eva R. Birnbaum, Jonathan W. Engle, Kevin D. John, Stosh A. Kozimor, Juan S. Lezama Pacheco, and Lindsay N. Redman. "Synthesis and Characterization of the Actinium Aquo Ion." ACS Central Science 3, no. 3 (February 2017): 176–85. http://dx.doi.org/10.1021/acscentsci.6b00356.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Abergel, Rebecca, and Leticia Arnedo-Sanchez. "Challenges of actinium coordination chemistry for nuclear medicine." Journal of Medical Imaging and Radiation Sciences 50, no. 4 (December 2019): S111. http://dx.doi.org/10.1016/j.jmir.2019.11.124.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Abergel, Rebecca, and Leticia Arnedo-Sanchez. "Challenges of actinium coordination chemistry for nuclear medicine." Journal of Medical Imaging and Radiation Sciences 50, no. 1 (March 2019): S39. http://dx.doi.org/10.1016/j.jmir.2019.03.119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Al-DARGAZELLI, Shetha Selman, and Nejla'a Salih Al-ALI. "Actinium-228 in Natural Background Gamma Radiation Spectrum." Journal of Nuclear Science and Technology 23, no. 8 (August 1986): 740–44. http://dx.doi.org/10.1080/18811248.1986.9735047.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Sakamoto, Yoshiaki, Tomoaki Ishii, Satora Inagawa, Yasuyoshi Gunji, Shinichi Takebe, Hiromichi Ogawa, and Tomozo Sasaki. "Sorption Characteristics of Actinium and Protactinium onto Soils." Journal of Nuclear Science and Technology 39, sup3 (November 2002): 481–84. http://dx.doi.org/10.1080/00223131.2002.10875511.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Fry, C., and M. Thoennessen. "Discovery of actinium, thorium, protactinium, and uranium isotopes." Atomic Data and Nuclear Data Tables 99, no. 3 (May 2013): 345–64. http://dx.doi.org/10.1016/j.adt.2012.03.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Miller, Maurice O., and Dionne A. Miller. "The Technological Enhancement of Normally Occurring Radioactive Materials in Red Mud due to the Production of Alumina." International Journal of Spectroscopy 2016 (March 16, 2016): 1–6. http://dx.doi.org/10.1155/2016/4589460.

Full text
Abstract:
This study investigates the level of technological enhancement of normally occurring radioactive materials (TENORM) in the red mud waste due to the production of alumina in Jamaica. Technological enhancements factors (TEF) were determined for the uranium, thorium, actinium series, their progenies, and the nonseries potassium-40 using gamma spectrometry. The study concluded that bauxite production technologically enhances the uranium progenies Th-234, Pb-214, Bi-214, and Pa-234 and the thorium-232 progenies Ac-228, Pb-212, and Bi-212 in red mud. The actinium series was technologically enhanced, but K-40 and the thorium daughter, Tl-208, were reduced. The spectrometric comparison of Tl-208 (at 510 keV) was unexpected since its other photopeaks at 583 keV, 934 keV, and 968 keV were markedly different. An explanation for this anomaly is discussed. An explanation regarding the process of accumulation and fractionation of organically derived phosphate deposits and potassium-feldspar is offered to explain the spectrometric differences between the alumina product and its waste material, red mud.
APA, Harvard, Vancouver, ISO, and other styles
40

Harvey, James T. "NorthStar Perspectives for Actinium-225 Production at Commercial Scale." Current Radiopharmaceuticals 11, no. 3 (October 22, 2018): 180–91. http://dx.doi.org/10.2174/1874471011666180515123848.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Abou, Diane S., Patrick Zerkel, James Robben, Mark McLaughlin, Tim Hazlehurst, David Morse, Thaddeus J. Wadas, et al. "Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies." Cancer Biotherapy and Radiopharmaceuticals 37, no. 5 (June 1, 2022): 355–63. http://dx.doi.org/10.1089/cbr.2022.0010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Weigand, Anna, Xiaoyan Cao, Tim Hangele, and Michael Dolg. "Relativistic Small-Core Pseudopotentials for Actinium, Thorium, and Protactinium." Journal of Physical Chemistry A 118, no. 13 (March 25, 2014): 2519–30. http://dx.doi.org/10.1021/jp500215z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Thierer, Laura M., and Neil C. Tomson. "The Actinium Aqua Ion: A Century in the Making." ACS Central Science 3, no. 3 (March 7, 2017): 153–55. http://dx.doi.org/10.1021/acscentsci.7b00074.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Young Oh, Se, Kyo Chul Lee, Ilhan Lim, Haijo Jung, and Sang Moo Lim. "Development of Actinium-225 Production Method using Liquid Target." Journal of Medical Imaging and Radiation Sciences 50, no. 4 (December 2019): S75. http://dx.doi.org/10.1016/j.jmir.2019.11.032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Cutler, C. "US DOE tri-lab effort to produce actinium-225." Nuclear Medicine and Biology 72-73 (July 2019): S8. http://dx.doi.org/10.1016/s0969-8051(19)30212-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Zhang, Chao, Zhi-Jian Li, Hong Jiang, Xue-Ning Hu, Guo-Hua Zhong, and Yue-Hua Su. "Thermodynamic and mechanical properties of actinium and lanthanum dihydride." Journal of Alloys and Compounds 616 (December 2014): 42–46. http://dx.doi.org/10.1016/j.jallcom.2014.07.087.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Young Oh, Se, Kyo Chul Lee, Ilhan Lim, Haijo Jung, and Sang Moo Lim. "Development of Actinium-225 Production Method using Liquid Target." Journal of Medical Imaging and Radiation Sciences 50, no. 1 (March 2019): S9. http://dx.doi.org/10.1016/j.jmir.2019.03.027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Kennel, Stephen J., Martin W. Brechbiel, Diane E. Milenic, Jeffrey Schlom, and Saed Mirzadeh. "Actinium-225 Conjugates of MAb CC49 and Humanized ΔCH2CC49." Cancer Biotherapy and Radiopharmaceuticals 17, no. 2 (April 2002): 219–31. http://dx.doi.org/10.1089/108497802753773847.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Deal, Kim A., Ila A. Davis, Saed Mirzadeh, Stephen J. Kennel, and Martin W. Brechbiel. "Improved in Vivo Stability of Actinium-225 Macrocyclic Complexes." Journal of Medicinal Chemistry 42, no. 15 (July 1999): 2988–92. http://dx.doi.org/10.1021/jm990141f.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Chen, Xiaoyuan, Min Ji, Chien M. Wai, Xiaoyuan Chen, and Darrell R. Fisher. "Carboxylate-derived calixarenes with high selectivity for actinium-225." Chemical Communications, no. 3 (1998): 377–78. http://dx.doi.org/10.1039/a706776c.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Actinium' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography